1. The solid dispersion of at least one polymeric pharmaceutical excipient and rasagiline or a pharmaceutically acceptable soli.2. The solid dispersion according to claim 1, wherein at least one pharmaceutical excipient is a polymeric water-soluble polymer to pharmaceutical ekstsipientom.3. The solid dispersion according to claim 1, wherein the pharmaceutically acceptable salt of rasagiline is rasagiline citrate, preferably monosubstituted razagilina.4 citrate. The solid dispersion according to claim 1, wherein at least one polymeric pharmaceutical excipient is polyvinylpyrrolidone, hydroxypropylmethylcellulose acetate succinate or hydroxypropylmethylcellulose phthalate gidroksipropilmetiltsellyulozy.5. The solid dispersion according to claim 1, wherein at least one polymer is a copolymer of pharmaceutical excipient, preferably a polyvinylpyrrolidone-vinyl acetate copolymer or methacrylic acid with etilakrilatom.6. The solid dispersion according to claim 1, wherein Ttverdoy dispersion is at least 20 ° C above the glass transition temperature of rasagiline or a pharmaceutically acceptable soli.7. A pharmaceutical composition comprising a solid dispersion according to any one pp.1-6.8. A method for producing a solid dispersion of rasagiline citrate of any one of claims 1-6, comprising: a) combining the mixture of rasagiline free base and at least one polymeric pharmaceutical excipient in a solvent to form a solution b) adding citric acid solution and c) removing solvent from rastvora.9. A method according to claim 8, wherein the solvent is methanol, ethanol, acetone, dichloromethyl1. Твердая дисперсия по меньшей мере одного полимерного фармацевтического эксципиента и разагилина или его фармацевтически приемлемой соли.2. Твердая дисперсия по п.1, в которой по меньшей мере один полимерный фармацевтический эксципиент является водорастворимым полимерным фармацевтическим эксципиентом.3. Твердая дисперсия по п.1, в которой фармацевтически приемлемая соль разагилина является
